Effect of Regorafenib in Delaying Definitive Deterioration in Health-Related Quality of Life in Patients with Advanced Cancer of Three Different Tumor Types

摘要

The efficacy and safety of regorafenib have been demonstrated in phase 3 trials for multiple tumor types, including metastatic colorectal cancer (mCRC) (CORRECT [{"type":"clinical-trial","attrs":{"text":"NCT01103323","term_id":"NCT01103323"}}NCT01103323]; CONCUR [{"type":"clinical-trial","attrs":{"text":"NCT01584830","term_id":"NCT01584830"}}NCT01584830]), advanced gastrointestinal stromal tumor (GIST) (GRID [{"type":"clinical-trial","attrs":{"text":"NCT01271712","term_id":"NCT01271712"}}NCT01271712]), and hepatocellular carcinoma (HCC) (RESORCE [{"type":"clinical-trial","attrs":{"text":"NCT01774344","term_id":"NCT01774344"}}NCT01774344]). The objective of this post hoc exploratory analysis was to explore the impact of regorafenib on delaying health-related quality of life (HRQOL) deterioration across these tumor types.